Noom Med Reviews Semaglutide
First-line, with asynchronous-first intake and nurse-practitioner review. The low-friction pathway that drives Noom's category-leading enrollment also removes most of the brakes on initiation.
Sold as Wegovy, Ozempic, Rybelsus · Reviewed September 19, 2026
What “First-line” means here
Prescribed as a first-line option. No lower-cost trial is required before a member can start.
The pairing
How Noom Med handles Semaglutide
These are the vendor-specific mechanics that determine what this molecule actually costs you and whether members stay on it long enough to benefit.
- Access status
- First-line
- Gating
- BMI ≥ 27. No step therapy and no prior authorization requirement from Noom itself.
- Prescribes directly
- Yes
- Step therapy
- No
- Prior authorization
- No
- Titration protocol
- Asynchronous-first with NP review; synchronous visits available on request
- Off-ramp
- Behavioral maintenance track carried over from the consumer product
- Care team
- Nurse practitioners, Physician oversight, Behavioral coaches
Ask Noom Med this
What is the median time from signup to first semaglutide prescription, and how many synchronous clinical touchpoints occur before it is written?
Watch out
High enrollment is a cost risk, not just a win. Model what happens if uptake lands at the top of Noom's range.
The molecule
Semaglutide in one page
The molecule that created this market. Weekly injectable GLP-1 agonist, the most widely prescribed agent across employer programs and the one your pharmacy trend is most likely driven by.
Clinical profile
- Drug class
- GLP-1 receptor agonist
- Brand names
- Wegovy — Chronic weight managementOzempic — Type 2 diabetesRybelsus — Type 2 diabetes (oral)
- Mechanism
- Mimics endogenous GLP-1: slows gastric emptying, increases satiety signaling, and stimulates glucose-dependent insulin secretion. The appetite effect, not the glycemic effect, drives the weight outcome.
- Administration
- Once-weekly subcutaneous injection. An oral daily formulation exists but is indicated for type 2 diabetes rather than weight management.
- Titration
- Typically initiated at a low weekly dose and escalated in steps roughly every four weeks over four to five months to the maintenance dose. That escalation window is where most discontinuation happens.
- Typical result
- In registrational trials, average body-weight reduction in the mid-teens as a percentage at roughly 68 weeks. Real-world results run materially lower, driven almost entirely by discontinuation rather than by non-response.
- Generic available
- No
Known side effects
- Gastrointestinal effects — nausea, vomiting, diarrhea, constipation — concentrated during dose escalation
- Gallbladder events and pancreatitis reported at low rates
- Class boxed warning regarding thyroid C-cell tumors observed in rodents
- Meaningful lean-mass loss alongside fat mass during rapid reduction
What benefits teams need to know
Indication arbitrage is a real budget risk
The same molecule is marketed under different brands for diabetes and for weight management, at different price points and under different coverage rules. Programs that do not tightly specify which indication and which brand they cover routinely find spend landing somewhere they did not model.
Titration is where your money is won or lost
Members who discontinue during escalation generate close to a full course of cost and close to zero durable benefit. The single most valuable thing a clinical vendor can do for your budget on this molecule is keep people through the escalation window.
Supply has been volatile
Availability of this molecule has shifted more than once, and vendors whose pricing depended on non-standard supply have had to re-price. Ask any vendor how their semaglutide economics changed through those periods and why.
Alternatives
Other vendors and Semaglutide
Same molecule, materially different access rules. The status column is where the cost difference lives.
| Vendor | Access | Score | PMPM |
|---|---|---|---|
| Virta Health Metabolic specialist | Escalation only | 8.7 | $40–$95 |
| Omada Health Coaching companion | Companion support | 8.4 | $32–$58 |
| Form Health Full-service clinical | First-line | 8.0 | $58–$105 |
| Twin Health Metabolic specialist | Escalation only | 7.8 | $55–$120 |
| Found Full-service clinical | Escalation only | 7.6 | $45–$85 |
| Vida Health Full-service clinical | Escalation only | 7.5 | $38–$78 |
Same vendor
Noom Med across the formulary
How this vendor positions each molecule tells you more about its cost discipline than any single review does.
Available first-line on the same asynchronous pathway as semaglutide. Given tirzepatide's efficacy advantage, expect member preference to pull volume here once it is offered without a cost hierarchy.
Present in the formulary but not a meaningful gate. Noom's model does not depend on routing members through it before incretin therapy.